Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis (Q39328713)

11 September 2017

Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis (English)

1 reference

11 September 2017

1 reference

Han-Xiang Zhan

1

1 reference

11 September 2017

Lin Cong

2

1 reference

11 September 2017

Yu-Pei Zhao

3

1 reference

11 September 2017

Tai-Ping Zhang

4

1 reference

11 September 2017

Ge Chen

5

1 reference

11 September 2017

Li Zhou

6

1 reference

11 September 2017

Jun-Chao Guo

7

1 reference

11 September 2017

18 June 2012

1 reference

Journal of Surgical Oncology

11 September 2017

1 reference

11 September 2017

106

1 reference

11 September 2017

8

1 reference

11 September 2017

972-980

1 reference

Surgical management of pancreatic endocrine tumors

11 September 2017

1 reference

Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital

21 January 2018

1 reference

Surgical management of patients with insulinomas: Result of 292 cases in a single institution

21 January 2018

1 reference

PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding

21 January 2018

1 reference

TOR signaling in growth and metabolism

21 January 2018

1 reference

21 January 2018

mTOR and cancer therapy

1 reference

Common corruption of the mTOR signaling network in human tumors

21 January 2018

1 reference

Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway

21 January 2018

1 reference

Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis

21 January 2018

1 reference

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors

21 January 2018

1 reference

Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony

21 January 2018

1 reference

Current development of mTOR inhibitors as anticancer agents

21 January 2018

1 reference

The expanding TOR signaling network

21 January 2018

1 reference

Molecular mechanisms of mTOR-mediated translational control

21 January 2018

1 reference

Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors

21 January 2018

1 reference

Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer

21 January 2018

1 reference

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

The applicability of mTOR inhibition in solid tumors.

21 January 2018

1 reference

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer

21 January 2018

1 reference

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

21 January 2018

1 reference

Beta-cell gene expression and functional characterisation of the human insulinoma cell line CM.

21 January 2018

1 reference

Karyotype of the human insulinoma CM cell line--beta cell model in vitro?

21 January 2018

1 reference

The CM cell line derived from liver metastasis of malignant human insulinoma is not a valid beta cell model for in vitro studies

21 January 2018

1 reference

MnTMPyP, a metalloporphyrin-based superoxide dismutase/catalase mimetic, protects INS-1 cells and human pancreatic islets from an in vitro oxidative challenge

21 January 2018

1 reference

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR

21 January 2018

1 reference

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

21 January 2018

1 reference

The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins

21 January 2018

1 reference

Differential contribution to neuroendocrine tumorigenesis of parallel egfr signaling in cancer cells and pericytes

21 January 2018

1 reference

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

21 January 2018

1 reference

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

21 January 2018

1 reference

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

21 January 2018

1 reference

Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations

21 January 2018

1 reference

Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1210/ENDO.130.1.1370150

Identifiers

DOI

10.1002/JSO.23176

1 reference

11 September 2017

1 reference